Mumbai : Sai Parenterals Limited, which is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing and it is in the business of branded generic formulations and contract development and manufacturing organisation (CDMO) products, has garnered Rs 122.6 crore from anchor investors ahead of its initial public offering that opens for public subscription on Tuesday, March 24, 2026.

The company informed the bourses that it allocated 31,28,458 equity shares at Rs 392 per share to anchor investors.

Some of the marquee institutions that participated in the anchor include Morgan Stanley (Asia) Singapore Pte, Kotak Mahindra Life Insurance Company, Kotak Life Sciences Fund 1 and India Emerging Funds Limited.

Amongst equity- oriented schemes, the company has allocated shares to Quant Mutual Fund – Quant Momentum Fund.

Out of the total allocation of 31,28,485 equity shares to the anchor investors, 9,18,384 were allocated to 1 domestic mutual fund through 1 scheme.

Arihant Capital Markets is the book-running lead manager, and Bigshare Services Private Limited is the registrar of the offer.